The Company welcomes new development partnerships and collaborations with both industry and academia for its proprietary oral T-cell activation therapy platform and product candidates. VAXIMM works with leading academic institutions and pharmaceutical companies in its development activities.
The Company is seeking funding to advance its COVID-19 vaccine development project.